Working... Menu
Trial record 61 of 877 for:    "Reticulum Cell Sarcoma"

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00275431
Recruitment Status : Completed
First Posted : January 12, 2006
Last Update Posted : June 29, 2011
Information provided by:
Ascenta Therapeutics

Brief Summary:
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.

Condition or disease Intervention/treatment Phase
Follicular Lymphoma Diffuse Large Cell Lymphoma Mantle Cell Lymphoma Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia Drug: AT-101 Phase 2

Detailed Description:
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies. For the purpose of this study, B-cell malignancies can include one of the following disease sub-types: follicular lymphoma (FL), diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia. Patients will be enrolled according to disease subtype into one of four groups in two stages. The first stage of each group will enrolled 13 patients. If patients within any group experience disease response, an additional 14 patients will be enrolled into that group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
Study Start Date : November 2005
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Intervention Details:
  • Drug: AT-101

Primary Outcome Measures :
  1. Complete or partial remission of disease. [ Time Frame: every 6 weeks ]

Secondary Outcome Measures :
  1. Number of participants with adverse events. [ Time Frame: every 3 weeks ]
  2. duration of response [ Time Frame: every 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have a histologically confirmed B-cell malignancy (defined as FL [any grade], DLBCL, MCL or SLL/CLL);
  • Male or non-pregnant, non-lactating females age ≥18 years;
  • Ability to swallow and retain oral medication.;
  • Have failed at least one prior therapy and have documentation of either, relapsed disease, or refractory disease (i.e., no response or stable disease on their last regimen of therapy);
  • ECOG performance status 0 or 1;
  • All clinically significant toxicities from prior therapy must have fully resolved;
  • Must have discontinued treatment with monoclonal antibodies for a minimum of 90 days prior to first dose of AT-101, or have objective documentation of disease progression if within 90 days of monoclonal antibody administration;
  • Patients with FL, DLBCL, MCL, and SLL with normal lymphocyte counts must have at least one bi-dimensional lesion that is radiographically measurable (skin lesions, palpable lymph nodes, and bone marrow as the only site of disease are not considered measurable disease);
  • Patients with SLL whose lymphocytes are elevated at baseline or CLL must have palpable lymph nodes and/or disease localized to the bone marrow per the NCI-Sponsored Working Group Guidelines for CLL.

Exclusion Criteria:

  • Requirement of systemic corticosteroids within 7 days prior to and during AT-101 administration;
  • Must not have received anti-cancer therapy within 28 days of first dose of AT-101. Cannot have received hormonal agents or biologic dose modifiers (with the exception of HRT) or any investigational treatments within 28 days of treatment with AT-101;
  • Patients with CNS lymphoma, HIV-related lymphoma, symptoms suggesting HIV infection or active auto-immune hemolytic anemia are excluded;
  • Previous treatment with gossypol, or are hypersensitive to its excipient are excluded;
  • Patients who have an uncontrolled, concurrent illness are also excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00275431

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, California
San Diego, California, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, New York
New York, New York, United States
Rochester, New York, United States
United States, North Carolina
High Point, North Carolina, United States
United States, South Carolina
Hilton Head Island, South Carolina, United States
United States, Tennessee
Memphis, Tennessee, United States
United States, Vermont
Burlington, Vermont, United States
Sponsors and Collaborators
Ascenta Therapeutics
Layout table for investigator information
Study Director: Lance Leopold, MD Ascenta Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Lance Leopold, Ascenta Therapeutics, Inc. Identifier: NCT00275431     History of Changes
Other Study ID Numbers: AT-101-CS-005
First Posted: January 12, 2006    Key Record Dates
Last Update Posted: June 29, 2011
Last Verified: June 2011

Keywords provided by Ascenta Therapeutics:
B-cell malignancies

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Lymphoma, B-Cell
Gossypol acetic acid
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Spermatocidal Agents
Antispermatogenic Agents
Contraceptive Agents, Male